Sex and gender in inflammatory bowel disease outcomes and research

Vibeke Andersen¹, Jessica Pingel², Heidi Lynge Søfelt², Zainab Hikmat², Mads Johansson³, Vera Slyk Pedersen⁴, Benthe Bertelsen⁴, Anne Carlsson⁵, Marie Lindh⁶, Edda Svavarsdóttir⁷, Dirk Repsilber⁸, Maiken Thyregod Joergensen⁹, Robin Christensen¹⁰, Anja Fejrskov¹¹, Johannes David Füchtbauer¹², Jens Kjeldsen¹³, Michael Dam Jensen¹⁴, Claus Aalykke¹⁵, Martin Rejler¹⁶, Marte Lie Høivik¹⁷, Loa Davidsdottir¹⁸, Marie Carlson¹⁹, Jonas Halfvarson²⁰, Heidi Holt Zachariassen²¹, Liv Baisner Petersen²², Eva Sophia Myers²²

Affiliations

¹ Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Molecular Diagnostics and Clinical Research Unit, Department of Internal Medicine, University Hospital of Southern Denmark, Aabenraa, Denmark. Electronic address: va@rsyd.dk.
² Molecular Diagnostics and Clinical Research Unit, Department of Internal Medicine, University Hospital of Southern Denmark, Aabenraa, Denmark.
³ Mage-tarmforbundet, Nes, Norway.
⁴ The Danish Colitis Crohn Association, Odense, Denmark.
⁵ Tarm-uro-och stomiförbundet ILCO, Stockholm, Sweden.
⁶ The Swedish Stomach and Bowel Association, Stockholm, Sweden.
⁷ Crohn's og Colitis Ulcerosa Samtökin, Reykjavik, Iceland.
⁸ School of Medical Sciences, University of Örebro, Örebro, Sweden.
⁹ Department of Medical Gastroenterology, University Hospital of Southern Denmark, Vejle, Denmark.
¹⁰ Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark.
¹¹ Molecular Diagnostics and Clinical Research Unit, Department of Internal Medicine, University Hospital of Southern Denmark, Aabenraa, Denmark; Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.
¹² Research Unit of Medical Gastroenterology, University of Southern Denmark, Odense, Denmark; Research Unit of Medicine Svendborg, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark; Department of Internal Medicine and Emergency, Section of Gastroenterology Svendborg, Odense University Hospital and Svendborg Hospital, Odense, Denmark.
¹³ Research Unit of Medical Gastroenterology, University of Southern Denmark, Odense, Denmark; Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.
¹⁴ Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark; Department of Internal Medicine, Section of Gastroenterology, Hospital of South West Jutland and University Hospital of Southern Denmark, Esbjerg, Denmark.
¹⁵ Research Unit of Medicine Svendborg, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Internal Medicine and Emergency, Section of Gastroenterology Svendborg, Odense University Hospital and Svendborg Hospital, Odense, Denmark.
¹⁶ Jönköping Academy for Improvement in Health and Welfare, Jönköping University, Jönköping, Sweden; Futurum Academy for Healthcare, Jönköping, Sweden.
¹⁷ Department of Gastroenterology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
¹⁸ Department of Gastroenterology, Landspitali University Hospital, Reykjavík, Iceland.
¹⁹ Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden.
²⁰ Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
²¹ Committee for Gender Balance and Diversity in Research, Universitets og høgskolerådet, Oslo, Norway.
²² Gender Equality Team, University of Southern Denmark, Odense, Denmark.

PMID: 39395438
DOI: 10.1016/S2468-1253(24)00159-6

Review

Sex and gender in inflammatory bowel disease outcomes and research

Vibeke Andersen et al. Lancet Gastroenterol Hepatol. 2024 Nov.

. 2024 Nov;9(11):1041-1051.

doi: 10.1016/S2468-1253(24)00159-6.

Authors

Affiliations

¹ Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Molecular Diagnostics and Clinical Research Unit, Department of Internal Medicine, University Hospital of Southern Denmark, Aabenraa, Denmark. Electronic address: va@rsyd.dk.
² Molecular Diagnostics and Clinical Research Unit, Department of Internal Medicine, University Hospital of Southern Denmark, Aabenraa, Denmark.
³ Mage-tarmforbundet, Nes, Norway.
⁴ The Danish Colitis Crohn Association, Odense, Denmark.
⁵ Tarm-uro-och stomiförbundet ILCO, Stockholm, Sweden.
⁶ The Swedish Stomach and Bowel Association, Stockholm, Sweden.
⁷ Crohn's og Colitis Ulcerosa Samtökin, Reykjavik, Iceland.
⁸ School of Medical Sciences, University of Örebro, Örebro, Sweden.
⁹ Department of Medical Gastroenterology, University Hospital of Southern Denmark, Vejle, Denmark.
¹⁰ Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark and Odense University Hospital, Odense, Denmark.
¹¹ Molecular Diagnostics and Clinical Research Unit, Department of Internal Medicine, University Hospital of Southern Denmark, Aabenraa, Denmark; Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.
¹² Research Unit of Medical Gastroenterology, University of Southern Denmark, Odense, Denmark; Research Unit of Medicine Svendborg, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark; Department of Internal Medicine and Emergency, Section of Gastroenterology Svendborg, Odense University Hospital and Svendborg Hospital, Odense, Denmark.
¹³ Research Unit of Medical Gastroenterology, University of Southern Denmark, Odense, Denmark; Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark.
¹⁴ Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark; Department of Internal Medicine, Section of Gastroenterology, Hospital of South West Jutland and University Hospital of Southern Denmark, Esbjerg, Denmark.
¹⁵ Research Unit of Medicine Svendborg, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Internal Medicine and Emergency, Section of Gastroenterology Svendborg, Odense University Hospital and Svendborg Hospital, Odense, Denmark.
¹⁶ Jönköping Academy for Improvement in Health and Welfare, Jönköping University, Jönköping, Sweden; Futurum Academy for Healthcare, Jönköping, Sweden.
¹⁷ Department of Gastroenterology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
¹⁸ Department of Gastroenterology, Landspitali University Hospital, Reykjavík, Iceland.
¹⁹ Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden.
²⁰ Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
²¹ Committee for Gender Balance and Diversity in Research, Universitets og høgskolerådet, Oslo, Norway.
²² Gender Equality Team, University of Southern Denmark, Odense, Denmark.

PMID: 39395438
DOI: 10.1016/S2468-1253(24)00159-6

Abstract

Extensive patient heterogeneity is a challenge in the management of inflammatory bowel disease (IBD). Sex and gender, as well as the interaction of sex and gender with other social identities, referred to as intersectionality, contribute to this heterogeneity and might affect IBD outcomes. An interdisciplinary team of clinicians, researchers, patients, and sex and gender experts reviewed current literature on the effect of sex and gender dimensions on IBD outcomes. The team also investigated the role that stakeholders have in advancing sex-based and gender-based IBD knowledge, as comprehensive studies are scarce. Acknowledging and integrating sex and gender into the organisation and content of research (eg, study design, participant recruitment, data analysis, data interpretation, data dissemination, and impact evaluation) could enhance the validity, relevance, and applicability of research. Such gendered innovation has potential for advancing personalised medicine and improving the quality of life for people with IBD.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JH has served as a speaker or advisory board member for AbbVie, Aqilion, Bristol Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, Meda Pharmaceuticals, Medivir, Novartis, Pfizer, Prometheus Laboratories, Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, and Union Chimique Belge, and has received grant support from Janssen, Merck Sharpe & Dohme, and Takeda. VA has served as an advisory board member for Merck Sharpe & Dohme. MDJ has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Tillotts Pharma, Takeda, Norgine, and Olympus. MR reports consulting fees from Janssen as part of a half-day advisory meeting concerning the use of a medication in clinical gastroenterology and payment from AbbVie as compensation for one lecture during Swedish Gastro Week on quality management within IBD; compensation for both was administrated as part of his job as a consultant of gastroenterology and hepatology. JDF reports support for attending meetings and travel from Tillotts and the Danish Society for Gastroenterology and Hepatology. MC has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Vifor Pharma. All other authors declare no competing interests.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Sex and gender in inflammatory bowel disease outcomes and research

Affiliations

Sex and gender in inflammatory bowel disease outcomes and research

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources